Can­cer Re­search UK spin­off rais­es $41M+ in Se­ries B in­jec­tion

The es­tro­gen re­cep­tor (ER) — which is in­hib­it­ed by tar­get­ed drugs such as the hor­mone ther­a­py ta­mox­ifen and aro­matase in­hibitors — is a tran­scrip­tion fac­tor im­pli­cat­ed in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER